Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice management and therapy notes software for mental health practitioners, acquired by Therapy Brands. Serves solo practices, group practices, and agencies.
TheraNest is a cloud-based practice management and clinical documentation platform for mental health practitioners, including therapists, social workers, counselors, and psychologists. Originally founded as an independent company, TheraNest was acquired by Therapy Brands, a technology roll-up focused on behavioral health software, which also owns Therapy Brands, ICANotes, and other mental health practice management systems. TheraNest serves a broad range of practice types from solo practitioners to large group practices and nonprofit agencies.\n\nThe platform provides scheduling, billing, telehealth, clinical notes, treatment planning, and client portal functionality in a unified interface. TheraNest is particularly recognized for its affordability and straightforward pricing model, which has made it a popular choice for practices with tight administrative budgets and those serving Medicaid populations. The product supports both individual and group therapy documentation workflows, including co-signature and supervision features relevant to practices employing pre-licensed associates.\n\nAs part of the Therapy Brands portfolio, TheraNest benefits from shared infrastructure investment and cross-selling opportunities, while maintaining its standalone brand and product identity. The mental health EHR market is competitive, with SimplePractice, TherapyNotes, and Jane App also vying for the small-to-mid-size practice segment. TheraNest's acquisition has allowed it to invest in product development while leveraging Therapy Brands' broader customer relationships and compliance infrastructure.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.